Department of Endocrinology and Nephrology, University of Leipzig, Liebigstr 18, 04103 Leipzig, Germany.
Diabetologia. 2013 Jan;56(1):10-21. doi: 10.1007/s00125-012-2737-4. Epub 2012 Sep 29.
Adipocyte fatty acid binding protein (AFABP, also known as aP2 and FABP4) has recently been introduced as a novel fat-derived circulating protein. AFABP serum concentrations are positively correlated with markers of the metabolic syndrome and vascular disease in various cross-sectional and interventional studies. Furthermore, a small set of prospective studies indicates that high AFABP serum levels at baseline predict the risk for metabolic and vascular morbidity and mortality. Studies in Afabp (also known as Fabp4) knockout mice and AFABP inhibitor-treated animals suggest that total AFABP promotes insulin resistance, hypertriacylglycerolaemia and atherosclerosis by ligand/ligand delivery, as well as ligand-independent mechanisms. In contrast, the pathophysiological significance of circulating AFABP and the mechanisms leading to its release remain to be established. The current review summarises recent findings on the regulation and potential role of AFABP in metabolic and vascular disease.
脂肪细胞脂肪酸结合蛋白（AFABP，也称为 aP2 和 FABP4）最近被作为一种新型的脂肪衍生循环蛋白引入。在各种横断面和干预研究中，AFABP 血清浓度与代谢综合征和血管疾病的标志物呈正相关。此外，一小部分前瞻性研究表明，基线时高 AFABP 血清水平预测代谢和血管发病率和死亡率的风险。在 Afabp（也称为 Fabp4）基因敲除小鼠和用 AFABP 抑制剂治疗的动物的研究中，表明总 AFABP 通过配体/配体传递以及配体非依赖性机制促进胰岛素抵抗、高三酰甘油血症和动脉粥样硬化。相比之下，循环 AFABP 的病理生理学意义及其释放的机制仍有待确定。本综述总结了关于 AFABP 在代谢和血管疾病中的调节和潜在作用的最新发现。
